We also evaluated the prognostic value of VSTM2L in cancer and investigated the relationship between VSTM2L expression level and various aspects of the TIME including immune cell infiltration, expression of immunomodulators (such as immunostimulators, immunoinhibitors, and major histocompatibility complex (MHC) molecules), tumor mutation burden (TMB), microsatellite instability (MSI), and Immune/StromalScores. This evidence concerns the gene VSTM2L and cancer.